​
​

Voyager Therapeutics (VYGR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

VYGR Stock Forecast

Voyager Therapeutics stock forecast is as follows: an average price target of $15.20 (represents a 188.43% upside from VYGR’s last price of $5.27) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

VYGR Price Target

The average price target for Voyager Therapeutics (VYGR) is $15.20 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $18.00 to $8.00. This represents a potential 188.43% upside from VYGR's last price of $5.27.

VYGR Analyst Ratings

Buy

According to 3 Wall Street analysts, Voyager Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for VYGR stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Voyager Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 13, 2024Jay OlsonOppenheimer$18.00$6.92160.12%241.56%
Sep 25, 2024Jack AllenRobert W. Baird$18.00$6.04198.01%241.56%
May 14, 2024Laura ChicoWedbush$8.00$8.48-5.66%51.80%
Jan 02, 2024Jim BirchenoughWells Fargo$14.00$9.0055.56%165.65%
May 10, 2023Joon LeeTruist Financial$18.00$9.8882.19%241.56%
Row per page
Go to

The latest Voyager Therapeutics stock forecast, released on Nov 13, 2024 by Jay Olson from Oppenheimer, set a price target of $18.00, which represents a 160.12% increase from the stock price at the time of the forecast ($6.92), and a 241.56% increase from VYGR last price ($5.27).

Voyager Therapeutics Price Target by Period

1M3M12M
# Anlaysts124
Avg Price Target$18.00$18.00$14.50
Last Closing Price$5.27$5.27$5.27
Upside/Downside241.56%241.56%175.14%

In the current month, the average price target of Voyager Therapeutics stock is $18.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 241.56% increase as opposed to Voyager Therapeutics's last price of $5.27. This month's average price target is down 0.00% compared to last quarter, and up 24.14% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 13, 2024OppenheimerOutperformOutperformHold
Oct 16, 2024WedbushBuyBuyHold
Jul 31, 2024WedbushBuyBuyHold
May 14, 2024WedbushNeutralNeutralHold
May 10, 2023UBS-BuyInitialise
Row per page
Go to

Voyager Therapeutics's last stock rating was published by Oppenheimer on Nov 13, 2024. The company gave VYGR a "Outperform" rating, the same as its previous rate.

Voyager Therapeutics Financial Forecast

Voyager Therapeutics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue--------------$4.85M$150.48M$-41.09M$41.09M$712.00K$658.00K$28.07M$1.48M$1.36M$6.50M$6.54M$117.84M$28.68M$18.07M$32.67M$20.43M
Avg Forecast$39.80M$37.74M$35.78M$33.92M$7.03M$12.53M$12.31M$7.03M$14.79M$11.70M$9.51M$9.48M$20.63M$2.91M$1.60M$10.04M$3.73M$9.42M$7.03M$12.71M$4.30M$2.14M$4.18M$7.55M$16.59M$15.05M$16.52M$13.55M$9.93M$6.88M
High Forecast$66.84M$63.37M$60.07M$56.95M$11.81M$21.03M$20.67M$13.36M$23.00M$12.20M$9.51M$15.92M$23.05M$2.91M$2.69M$16.86M$6.27M$9.42M$7.03M$12.71M$4.30M$2.14M$4.18M$7.55M$16.59M$15.05M$16.52M$13.55M$9.93M$6.88M
Low Forecast$9.75M$9.24M$8.76M$8.31M$1.72M$3.07M$3.02M$703.37K$3.71M$11.21M$9.51M$2.32M$19.22M$2.91M$392.29K$2.46M$913.96K$9.42M$7.03M$12.71M$4.30M$2.14M$4.18M$7.55M$16.59M$15.05M$16.52M$13.55M$9.93M$6.88M
# Analysts222211147344544433334444999955
Surprise %--------------3.03%14.99%-11.01%4.36%0.10%0.05%6.53%0.69%0.33%0.86%0.39%7.83%1.74%1.33%3.29%2.97%

Voyager Therapeutics's average Quarter revenue forecast for Sep 23 based on 4 analysts is $2.91M, with a low forecast of $2.91M, and a high forecast of $2.91M. VYGR's average Quarter revenue forecast represents a -40.09% decrease compared to the company's last Quarter revenue of $4.85M (Jun 23).

Voyager Therapeutics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts222211147344544433334444999955
EBITDA--------------$-25.43M$122.88M$-24.56M$15.78M$-18.16M$-18.54M$7.19M$-23.91M$-28.93M$-20.38M$-14.94M$86.67M$-7.75M$-23.42M$-11.82M$-14.29M
Avg Forecast$-14.17M$-13.44M$-12.74M$-12.08M$-2.50M$-4.46M$-4.38M$-2.50M$-5.27M$-4.17M$-3.39M$4.46M$-7.35M$-1.04M$-570.35K$4.77M$-17.21M$-3.40M$-2.54M$5.10M$-1.55M$-774.39K$-1.51M$-22.84M$-5.99M$-5.44M$-5.97M$-27.28M$-3.59M$-2.48M
High Forecast$-3.47M$-3.29M$-3.12M$-2.96M$-613.42K$-1.09M$-1.07M$-250.46K$-1.32M$-3.99M$-3.39M$5.35M$-6.84M$-1.04M$-139.69K$5.72M$-13.77M$-3.40M$-2.54M$6.12M$-1.55M$-774.39K$-1.51M$-18.28M$-5.99M$-5.44M$-5.97M$-21.82M$-3.59M$-2.48M
Low Forecast$-23.80M$-22.56M$-21.39M$-20.28M$-4.21M$-7.49M$-7.36M$-4.76M$-8.19M$-4.34M$-3.39M$3.57M$-8.21M$-1.04M$-957.71K$3.81M$-20.65M$-3.40M$-2.54M$4.08M$-1.55M$-774.39K$-1.51M$-27.41M$-5.99M$-5.44M$-5.97M$-32.73M$-3.59M$-2.48M
Surprise %--------------44.58%25.77%1.43%-4.64%7.15%-3.64%-4.63%30.88%19.18%0.89%2.49%-15.93%1.30%0.86%3.29%5.75%

4 analysts predict VYGR's average Quarter EBITDA for Jun 23 to be $-570.35K, with a high of $-139.69K and a low of $-957.71K. This is -100.46% lower than Voyager Therapeutics's previous annual EBITDA (Mar 23) of $122.88M.

Voyager Therapeutics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts222211147344544433334444999955
Net Income--------------$-22.21M$124.04M$-23.63M$17.62M$-18.87M$-21.29M$5.71M$-25.14M$-30.12M$-21.65M$-15.93M$85.61M$-8.68M$-24.26M$-12.57M$-15.01M
Avg Forecast$-33.67M$-33.68M$-31.72M$-31.73M$-32.98M$-26.94M$-27.60M$-32.56M$-23.53M$-25.73M$-23.67M$-33.55M$-16.72M$-33.62M$-32.90M$-35.88M$-18.35M$-18.31M$-27.54M$-38.37M$-36.01M$-43.15M$-42.02M$-24.27M$-32.32M$-10.87M$-41.35M$-28.26M$-41.80M$-41.94M
High Forecast$-619.29K$-619.40K$-583.43K$-583.64K$-606.52K$-495.55K$-507.71K$-17.14M$-7.46M$-473.30K$-435.33K$-26.84M$-14.45M$-618.32K$-605.22K$-28.70M$-14.68M$-18.31M$-27.54M$-30.70M$-36.01M$-43.15M$-42.02M$-19.42M$-32.32M$-10.87M$-41.35M$-22.60M$-41.80M$-41.94M
Low Forecast$-63.40M$-63.41M$-59.73M$-59.75M$-62.09M$-50.73M$-51.97M$-41.13M$-35.00M$-48.45M$-44.56M$-40.26M$-17.57M$-63.30M$-61.96M$-43.06M$-22.02M$-18.31M$-27.54M$-46.05M$-36.01M$-43.15M$-42.02M$-29.13M$-32.32M$-10.87M$-41.35M$-33.91M$-41.80M$-41.94M
Surprise %--------------0.67%-3.46%1.29%-0.96%0.69%0.55%-0.16%0.58%0.72%0.89%0.49%-7.88%0.21%0.86%0.30%0.36%

Voyager Therapeutics's average Quarter net income forecast for Jun 23 is $-32.90M, with a range of $-61.96M to $-605.22K. VYGR's average Quarter net income forecast represents a -126.53% decrease compared to the company's last Quarter net income of $124.04M (Mar 23).

Voyager Therapeutics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts222211147344544433334444999955
SG&A--------------$8.29M$9.03M$8.46M$7.31M$7.55M$7.66M$8.35M$8.71M$10.44M$9.74M$8.27M$8.28M$8.24M$10.21M$9.89M$8.46M
Avg Forecast$19.49M$18.48M$17.52M$16.61M$3.44M$6.13M$6.03M$3.44M$7.24M$5.73M$4.66M$4.64M$10.10M$1.42M$784.40K$4.92M$1.83M$4.61M$3.44M$6.23M$2.10M$1.05M$2.04M$3.70M$8.12M$7.37M$8.09M$11.89M$4.86M$3.37M
High Forecast$32.73M$31.03M$29.42M$27.89M$5.78M$10.30M$10.12M$6.54M$11.27M$5.97M$4.66M$7.80M$11.29M$1.42M$1.32M$8.26M$3.07M$4.61M$3.44M$6.23M$2.10M$1.05M$2.04M$3.70M$8.12M$7.37M$8.09M$14.26M$4.86M$3.37M
Low Forecast$4.77M$4.53M$4.29M$4.07M$843.64K$1.50M$1.48M$344.46K$1.82M$5.49M$4.66M$1.14M$9.41M$1.42M$192.11K$1.20M$447.59K$4.61M$3.44M$6.23M$2.10M$1.05M$2.04M$3.70M$8.12M$7.37M$8.09M$9.51M$4.86M$3.37M
Surprise %--------------10.57%1.84%4.63%1.58%2.19%1.23%3.97%8.30%5.10%2.64%1.02%1.12%1.02%0.86%2.03%2.51%

Voyager Therapeutics's average Quarter SG&A projection for Sep 23 is $1.42M, based on 4 Wall Street analysts, with a range of $1.42M to $1.42M. The forecast indicates a -82.83% fall compared to VYGR last annual SG&A of $8.29M (Jun 23).

Voyager Therapeutics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts222211147344544433334444999955
EPS--------------$-0.51$3.05$-0.61$0.46$-0.49$-0.56$0.15$-0.67$-0.80$-0.58$-0.43$2.30$-0.23$-0.66$-0.35$-0.41
Avg Forecast$-0.58$-0.58$-0.55$-0.55$-0.57$-0.47$-0.48$-0.56$-0.41$-0.44$-0.41$-0.44$-0.29$-0.58$-0.57$-0.33$-0.55$-0.32$-0.48$-0.37$-0.62$-0.75$-0.73$-0.64$-0.56$-0.19$-0.72$-0.79$-0.72$-0.73
High Forecast$-0.01$-0.01$-0.01$-0.01$-0.01$-0.01$-0.01$-0.30$-0.13$-0.01$-0.01$-0.01$-0.25$-0.01$-0.01$-0.01$-0.01$-0.32$-0.48$-0.37$-0.62$-0.75$-0.73$-0.64$-0.56$-0.19$-0.72$-0.79$-0.72$-0.73
Low Forecast$-1.10$-1.10$-1.03$-1.03$-1.07$-0.88$-0.90$-0.71$-0.61$-0.84$-0.77$-0.83$-0.30$-1.09$-1.07$-0.61$-1.03$-0.32$-0.48$-0.37$-0.62$-0.75$-0.73$-0.64$-0.56$-0.19$-0.72$-0.79$-0.72$-0.73
Surprise %--------------0.90%-9.38%1.12%-1.45%1.03%1.51%-0.24%0.90%1.10%0.90%0.77%-12.21%0.32%0.84%0.48%0.56%

According to 4 Wall Street analysts, Voyager Therapeutics's projected average Quarter EPS for Jun 23 is $-0.57, with a low estimate of $-1.07 and a high estimate of $-0.01. This represents a -118.65% decrease compared to VYGR previous annual EPS of $3.05 (Mar 23).

Voyager Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
XFORX4 Pharmaceuticals$0.37$3.67891.89%Buy
INZYInozyme Pharma$2.81$14.67422.06%Buy
PDSBPDS Bio$2.10$9.00328.57%Buy
ABOSAcumen Pharmaceuticals$2.39$7.00192.89%Buy
VYGRVoyager Therapeutics$5.27$15.20188.43%Buy
DAWNDay One Biopharmaceuticals$13.52$38.80186.98%Buy
ANNXAnnexon$5.46$14.00156.41%Buy
ARWRArrowhead Pharmaceuticals$18.60$45.38143.98%Buy
TERNTerns Pharmaceuticals$5.91$14.25141.12%Buy
LPTXLeap Therapeutics$2.70$5.50103.70%Buy
MREOMereo BioPharma Group$3.49$6.7593.41%Buy
HOOKHOOKIPA Pharma$2.79$3.007.53%Buy
PRQRProQR Therapeutics$3.60$3.630.83%Buy

VYGR Forecast FAQ

Is Voyager Therapeutics a good buy?

Yes, according to 3 Wall Street analysts, Voyager Therapeutics (VYGR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of VYGR's total ratings.

What is VYGR's price target?

Voyager Therapeutics (VYGR) average price target is $15.2 with a range of $8 to $18, implying a 188.43% from its last price of $5.27. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Voyager Therapeutics stock go up soon?

According to Wall Street analysts' prediction for VYGR stock, the company can go up by 188.43% (from the last price of $5.27 to the average price target of $15.2), up by 241.56% based on the highest stock price target, and up by 51.80% based on the lowest stock price target.

Can Voyager Therapeutics stock reach $8?

VYGR's average twelve months analyst stock price target of $15.2 supports the claim that Voyager Therapeutics can reach $8 in the near future.

What is Voyager Therapeutics's current price target trend?

1 Wall Street analyst forecast a $18 price target for Voyager Therapeutics (VYGR) this month, up 241.56% from its last price of $5.27. Compared to the last 3 and 12 months, the average price target increased by 241.56% and increased by 175.14%, respectively.

What are Voyager Therapeutics's analysts' financial forecasts?

Voyager Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $38.9M (high $66.88M, low $8.51M), average EBITDA is $-13.853M (high $-3.03M, low $-23.815M), average net income is $-120M (high $-18.748M, low $-206M), average SG&A $19.05M (high $32.75M, low $4.17M), and average EPS is $-2.076 (high $-0.324, low $-3.56). VYGR's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $147.23M (high $247.23M, low $36.06M), average EBITDA is $-52.428M (high $-12.841M, low $-88.035M), average net income is $-131M (high $-2.406M, low $-246M), average SG&A $72.1M (high $121.08M, low $17.66M), and average EPS is $-2.261 (high $-0.0416, low $-4.257).

Did the VYGR's actual financial results beat the analysts' financial forecasts?

Based on Voyager Therapeutics's last annual report (Dec 2022), the company's revenue was $40.91M, beating the average analysts forecast of $32.89M by 24.36%. Apple's EBITDA was $-50.837M, beating the average prediction of $-18.055M by 181.57%. The company's net income was $-46.408M, missing the average estimation of $-103M by -54.75%. Apple's SG&A was $30.98M, beating the average forecast of $16.11M by 92.32%. Lastly, the company's EPS was $-1.21, missing the average prediction of $-1.711 by -29.28%. In terms of the last quarterly report (Jun 2023), Voyager Therapeutics's revenue was $4.85M, beating the average analysts' forecast of $1.6M by 202.99%. The company's EBITDA was $-25.426M, beating the average prediction of $-570K by 4357.97%. Voyager Therapeutics's net income was $-22.208M, missing the average estimation of $-32.905M by -32.51%. The company's SG&A was $8.29M, beating the average forecast of $784.4K by 957.37%. Lastly, the company's EPS was $-0.51, missing the average prediction of $-0.569 by -10.33%